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Abstract 
Purpose: The aim of the study was to identify clinical, radiological and immuno-histochemical 
factors that may help predict upgrade of invasive ductal cancers of no special type (IDC-NST) 
with a core biopsy grade of 2 to grade 3 on final histology. 
 
Methods: A prospectively maintained database of ultrasound visible solid masses was used 
to identify lesions yielding a core biopsy result of IDC-NST grade 2 who underwent immediate 
surgery yielding a grade 2 or grade 3 tumour. Associations were sought between the source 
of patient (screening/symptomatic), core biopsy receptor status and imaging findings and the 
grade of the excision specimen tumour. Statistical analysis, which included the chi-squared 
test, ROC curves and Cox regression analysis, was used to compare upgrade vs no upgrade for 
each factor. 
 
Results: 463 IDC-NST breast cancers of core biopsy grade 2 gave 344 grade 2 and 119 grade 3 
tumours at excision. Factors significantly associated with upgrade were large ultrasound (US) 
size, hyperechogencity, stiffness at shearwave elastography (SWE), calcification on 
mammography and oestrogen receptor (ER) and progesterone receptor (PR) negativity. 
Patient source, Human epidermal growth factor receptor 2 (HER-2) status, ultrasound (US) 
distal effect and mammographic spiculation were not significantly associated with chance of 
upgrade. On multivariate analysis, only US size maintained statistical significance.  
 
Conclusion: Oncologists and surgeons should be aware that lesions with a core biopsy 
diagnosis of grade 2 IDC-NST measuring over 15mm on US have a 37% chance of being grade 
3 on excision and this should be considered when deciding pre-operative management. 
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Introduction 
 
The use of Neoadjuvant chemotherapy (NACT) is becoming increasingly common in the 
clinical management of breast cancer {ADDIN CSL_CITATION { "citationID" : "a2ht547ougg", 
"citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10.1016/j.clon.2017.06.003", 
"ISSN" : "0936-6555", "abstract" : "Neoadjuvant treatment offers a number of benefits for 
patients with early breast cancer, and is an important option for consideration by 
multidisciplinary teams. Despite literature showing its efficacy, the use of neoadjuvant 
therapy varies widely. Here we discuss the clinical evidence supporting the use of 
neoadjuvant therapy in early stage breast cancer, including patient selection, monitoring 
response, surgery and radiotherapy considerations, with the aim of assisting multidisciplinary 
teams to determine patient suitability for neoadjuvant treatment.", "author" : [ { "dropping-
particle" : "", "family" : "Cain", "given" : "H.", "non-dropping-particle" : "", "parse-names" : 
false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Macpherson", "given" : "I. R.", "non-
dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" 
: "Beresford", "given" : "M.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" 
}, { "dropping-particle" : "", "family" : "Pinder", "given" : "S. E.", "non-dropping-particle" : "", 
"parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Pong", "given" : "J.", 
"non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", 
"family" : "Dixon", "given" : "J. M.", "non-dropping-particle" : "", "parse-names" : false, 
"suffix" : "" } ], "container-title" : "Clinical Oncology", "id" : "ITEM-1", "issue" : "10", "issued" 
: { "date-parts" : [ [ "2017", "10" ] ] }, "page" : "642-652", "title" : "Neoadjuvant Therapy in 
Early Breast Cancer: Treatment Considerations and Common Debates in Practice", "type" : 
"article-journal", "volume" : "29" }, "uri" : [ 
"http://zotero.org/users/local/N5k1xoZW/items/KEIR2A9L" ], "uris" : [ 
"http://zotero.org/users/local/N5k1xoZW/items/KEIR2A9L", 
"http://www.mendeley.com/documents/?uuid=4bfae2e9-a996-4910-9a59-c24367fd5900" ] 
} ], "mendeley" : { "formattedCitation" : "(1)", "plainTextFormattedCitation" : "(1)" }, 
"properties" : { "formattedCitation" : "(1)", "plainCitation" : "(1)" }, "schema" : 
"https://github.com/citation-style-language/schema/raw/master/csl-citation.json" }}. The 
benefits of NACT include down-staging the breast and axillary disease to allow less surgery as 
well as converting inoperable disease to operable (2). It is, however, important to clarify 
whether the patient requires chemotherapy before administration of NACT. This decision 
usually takes place in a multi-disciplinary team meeting. The initial diagnosis and decision for 
NACT is based on the breast and axillary core needle biopsy results as well as the clinical and 
imaging features of the tumour. An important factor in this decision is the grade of the tumour 
as high grade tumours are known to have a poorer prognosis but are more chemo-sensitive 
in comparison with lower grade tumours {ADDIN CSL_CITATION { "citationID" : 
"a1m71h77ono", "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10.1016/S0140-
6736(13)62422-8", "ISSN" : "0140-6736", "abstract" : "Summary\nPathological complete 
response has been proposed as a surrogate endpoint for prediction of long-term clinical 
benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We 
had four key objectives: to establish the association between pathological complete response 
and EFS and OS, to establish the definition of pathological complete response that correlates 
best with long-term outcome, to identify the breast cancer subtypes in which pathological 
complete response is best correlated with long-term outcome, and to assess whether an 
increase in frequency of pathological complete response between treatment groups predicts 
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improved EFS and OS. We searched PubMed, Embase, and Medline for clinical trials of 
neoadjuvant treatment of breast cancer. To be eligible, studies had to meet three inclusion 
criteria: include at least 200 patients with primary breast cancer treated with preoperative 
chemotherapy followed by surgery; have available data for pathological complete response, 
EFS, and OS; and have a median follow-up of at least 3 years. We compared the three most 
commonly used definitions of pathological complete response\u2014ypT0 ypN0, ypT0/is 
ypN0, and ypT0/is\u2014for their association with EFS and OS in a responder analysis. We 
assessed the association between pathological complete response and EFS and OS in various 
subgroups. Finally, we did a trial-level analysis to assess whether pathological complete 
response could be used as a surrogate endpoint for EFS or OS. We obtained data from 12 
identified international trials and 11\u2008955 patients were included in our responder 
analysis. Eradication of tumour from both breast and lymph nodes (ypT0 ypN0 or ypT0/is 
ypN0) was better associated with improved EFS (ypT0 ypN0: hazard ratio [HR] 0\u00b744, 
95% CI 0\u00b739\u20130\u00b751; ypT0/is ypN0: 0\u00b748, 
0\u00b743\u20130\u00b754) and OS (0\u00b736, 0\u00b730\u20130\u00b744; 
0\u00b736, 0\u00b731\u20130\u00b742) than was tumour eradication from the breast 
alone (ypT0/is; EFS: HR 0\u00b760, 95% CI 0\u00b755\u20130\u00b766; OS 0\u00b751, 
0\u00b745\u20130\u00b758). We used the ypT0/is ypN0 definition for all subsequent 
analyses. The association between pathological complete response and long-term outcomes 
was strongest in patients with triple-negative breast cancer (EFS: HR 0\u00b724, 95% CI 
0\u00b718\u20130\u00b733; OS: 0\u00b716, 0\u00b711\u20130\u00b725) and in those 
with HER2-positive, hormone-receptor-negative tumours who received trastuzumab (EFS: 
0\u00b715, 0\u00b709\u20130\u00b727; OS: 0\u00b708, 0\u00b703, 0\u00b722). In the 
trial-level analysis, we recorded little association between increases in frequency of 
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dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" 
: "Wolmark", "given" : "Norman", "non-dropping-particle" : "", "parse-names" : false, "suffix" 
: "" }, { "dropping-particle" : "", "family" : "Bonnefoi", "given" : "Herv\u00e9", "non-dropping-
particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : 
"Cameron", "given" : "David", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" 
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"parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Valagussa", "given" 
: "Pinuccia", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-
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estimated grade of the tumour on core biopsy is therefore important when deciding patient 
management pre-operatively. 
 
Multiple studies have shown that the upgrade rate of all grades 1 and 2 IDC-NST breast 
cancers on final histology, from core to excision biopsy, is between 13-25% (4-9). These 
patients may be denied NACT based on their estimated core needle biopsy grade when in fact 
they may have benefited from such therapy. There have been attempts to reduce the upgrade 
rate by modifying the grade definitions at core biopsy, however these modifications are yet 
to gain widespread acceptance (10,11). Upgrades are more common in ductal cancers than 
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lobular cancers because the proportion of lobular cancers which are grade 3 is lesser than 
ductal cancers. 
 
A number of previous studies have shown correlations between imaging features and 
histological grade, in particular, mammographic calcification has been shown to be a high-
grade feature (12), whereas spiculation is more common in low grade lesions (13).  At 
ultrasound (US), a well-circumscribed margin and distal bright up (acoustic enhancement) are 
common features of high grade (13), especially triple negative tumours (14-16). Shearwave 
elastography (SWE) is an ultrasound technique gaining widespread acceptance and stiffness 
at SWE has been shown to be associated with high histological grade (17). High grade cancers 
are known to be more common in symptomatic cancers compared to screen detected cancers 
(18). The aim of the study was to identify clinical, radiological and immunohistochemical 
factors that may help predict upgrade of IDC-NST tumours with a core biopsy grade of 2 to 
grade 3 on final histology of the excision specimen.  
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Methods 
A prospectively maintained database of ultrasound visible solid masses has been kept since 
January 2010. The requirement for patient consent was waived by the local ethics committee.  
Parameters such as US size, stiffness at SWE, the source of the patient 
(screening/symptomatic), core biopsy grade, receptor status and final histopathological 
features were also collected prospectively. The assessment of hormone receptor status (ER, 
PR, HER2) were carried out as described (19). HER2 testing was in line with UK guidelines (20). 
CNB was performed using a 14 gauge needle under US control with two passes through the 
region of interest. Lesions yielding a core biopsy result of IDC-NST grade 2 who underwent 
immediate surgery yielding a grade 2 or grade 3 tumour were the study group. 
 
An experienced breast radiologist, who was blinded to the histopathological outcome, 
conducted a retrospective analysis of greyscale US and mammographic features. Particularly, 
attention was given to features previously shown to be associated with histological grade. US 
features collected included echogenicity (hypoechoic, isoechoic, hyperechoic and 
heterogenous), distal effect (shadowing, none, enhancement) lesion orientation and whether 
the lesion was circumscribed. Mammographic features documented were the presence or 
absence of spiculation and calcification.  
 
Associations between individual parameters and upgrade from grade 2 to grade 3 were 
performed using the chi-squared test and chi-squared test for trend. For continuous variables, 
ROC curves were generated and the area under the curve (AOC) measured. Multivariate 
analysis using Cox regression analysis was performed including those factors shown to be 
statistically significant at univariate analysis. Medcalc software (version) was used for 
statistical analysis. 
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Results 
A total of 490 invasive IDC-NST breast tumours of core biopsy grade 2, treated by immediate 
excision were identified. The age range was 23-91 with a mean age of 62 years. The number 
of breast tumours that remained grade 2, were upgraded to grade 3 or downgraded to grade 
1 on excision from core biopsy grade 2 were 344 (70.1%), 119 (24.2%) and 27 (5.5%) 
respectively. Breast lesions that were downgraded were excluded from the study, as they did 
not meet inclusion criteria. This left a study group of 463 lesions. Table 1 summarises results 
from of clinic factors, mammographic and ultrasound features. 
 
Clinical factors 
Lesions presenting through screening had an upgrade rate of 21.7% (48/221) compared to 
symptomatic lesions where the upgrade rate was found to be 29.3 % (71/242). These 
differences were of borderline significance (p=0.06). 
Lesions in patients > 50 years old had an upgrade rate 26.3%(105/400) of compared to  22.2% 
(14/63) for those <= 50 years old. This difference was not statistically significant. 
 
Mammographic features 
Spiculated lesions had an upgrade rate of 23.6% (55/233) compared to non spiculated lesions 
which had an upgrade rate of 27.8% (64/230).  This difference was not statistically significant 
(p=0.30). 
Lesions which were calcific on mammography had an upgrade rate of 35.2% (upgrade 37, no 
upgrade 68) compared to 22.9% for non-calcific lesions (82/358). This difference was 
statistically significant (p=0.011)  
 
Ultrasound and Shearwave Elastography features 
The relationship between US size and upgrade is demonstrated in an ROC curve (figure 1) for 
which a ROC curve was generated (Graph 1). The area under curve was 0.65 and (p = <0.0001) 
was statistically significant. The upgrade rate by US size group is shown in Table 2. 
 
US lesions that were circumscribed had an upgrade rate of 27.2% (22/81) compared with an 
upgrade rate of 25.4% for lesions that did not exhibit this feature (p=0.74) 
 
Lesions on US scan which were parallel had an upgrade rate of 27% (87/322) compared to 
22.7% for lesions that were non-parallel (p=0.33). 
 
Breast lesions that displayed a hyper-echoic element on US had an upgrade rate of 37.2% 
(29/78) compared to 23.4% (90/384) for those that did not exhibit this feature. The difference 
between these two groups was found to be statistically significant (p=0.01) 
 
Breast lesions that displayed enhancement for posterior effect had an upgrade rate of 34.9% 
(15/43) compared to 24.8% (104/419) for those that did not exhibit this feature (P=0.15). 
 
A ROC curve was generated for stiffness on SWE and upgrade. This showed an AUC of 0.56 
and the result was found to be statistically significant (p=0.037) with stiff lesions more likely 
to be upgraded.  
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Receptor Status 
An upgrade rate of 40% (14/35) was found in lesions that were HER2+ve compared to 25.4% 
(106/418) for HER2-ve lesions.  This difference was of borderline significance (p=0.059). A 
ROC curve was generated for ER receptor status which showed an AUC of 0.55 and a statistical 
significant result (p=0.034) associating ER negativity and upgrade. For PR receptor status, an 
ROC curve was also generated which showed an AOC of 0.55 and a statistical significant result 
(0.034) associating PR negativity and upgrade. 
 
Multivariate analysis 
On multivariate analysis of parameters significant at univariate analysis using Cox regression 
analysis only US size maintained statistical significance.  
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Discussion 
A number of clinical, radiological and immunohistochemical factors were analysed to study 
their value in predicting upgrade from a CNB estimate of IDC-NST grade 2 carcinoma to grade 
3 on excision. Although a number of factors had weak but significant associations with 
upgrade, the only factor with independent prediction of upgrade was found to be lesion size 
on US. The addition of other factors did not significantly improve upgrade prediction.   
 
Prognostic factors, such as receptor status, are known to correlate well between CNB and 
excision specimen (21, 22). On the other hand, grading on CNB is known to be less accurate 
with a concordance of 71.1% between core grade and excision grade on a recent meta-
analysis by Knuttel et al (23). Furthermore, this meta –analysis found there to be an issue of 
both over and underestimation of grade between CNB and excision in 9.3% (7.7-11.4%) and 
19.1% (17.1-21.3%) respectively. These findings are comparable to our study where we found 
over and underestimation in 5.5% and 24.2% respectively. Nonetheless, CNB grade estimation 
is useful in clinical practice and is used widely to guide pre-operative therapy.  
 
A number of studies have shown that a peak agreement for diagnosis of malignancy on CNB 
is achieved after 4-5 core biopsies are taken (24-27).  Histological grade, which is usually 
assessed using the Nottingham Scoring system, looks at tubular formation, nuclear 
pleomorphism and mitotic count has been widely accepted as an independent and significant 
prognostic factor in breast cancer (28). A major factor causing underestimation of histological 
grade at CNB is the mitotic count which may be underestimated due to the small sample size 
(29). Previous attempts at reducing the rate of upgrade have focused on histological factors 
such as mitotic count as concordance for mitotic count between core and excision specimen 
may be as low as 62.4% (23), however suggested alterations to grading practice for core  
biopsies to improve concordance are yet to gain wide-spread acceptance (10, 30). The 
heterogeneous nature of large breast tumours may also be a factor in producing an 
unrepresentative CNB samples (31). 
 
Currently, most centres will only perform two US guided core biopsies passes of an US visible 
mass routinely and only take more samples if the needle has missed the lesion on previous 
passes. It is likely that histological upgrade would be less frequent if more tissue was taken. 
This could either be achieved more passes using a 14 gauge CNB or using a vacuum assisted 
biopsy (VAB) device to increase the size of each core. The use of VAB has previously been 
shown to significantly reduce the upgrade rate from DCIS at biopsy to invasion at excision (32, 
33). However, we are not aware of any studies using VAB to achieve greater concordance 
between percutaneous biopsy and excision grade for invasive cancers. It is debatable whether 
the additional morbidity and cost is outweighed by the gain in grade consistency. However, a 
large American study has shown that VAB is more cost-effective than CNB, specifically 
tethered and large gauge VAB instruments, in the context of mean cost per diagnosis of 
malignancy (34).  However, such cost effective scenarios are likely to be very different in a 
European setting. 
 
Nonetheless, the importance of histological grade in estimating the need for, and sensitivity 
to NACT as well as the increased use of NACT means the balance between morbidity and cost 
compared with the benefits of accuracy of pre-operative grading needs revisiting. A number 
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of publications have emphasized the relationship between histological grade and chemo-
sensitivity (35, 36). Recent studies have focused on expression of cytokeratins (CK) which are 
intermediate filament proteins found in the cytoskeleton that suggest the epithelial cell type, 
tissue growth and differentiation of breast tumours. A large study has shown that expression 
of basal phenotype (CK 5/6, CK14) and ER –ve receptor status was significantly associated 
with histological grade 3 (37). Another study found that about 20% of ductal NST grade 3 
expressed CK14 (38). Currently, these markers are not used in routine practice but future 
research focusing on role of basal markers in predicting upgrade may be useful.  
 
Calcification at mammography is known to be associated with high grade invasive cancer, 
especially HER-2 positive disease (39).  The association we found between upgrade and 
mammographic calcification was therefore not surprising.  However hyperechogenicity of 
tumours on US is not known to be associated with high histological grade.  Our finding of an 
association between high upgrade rate in hyperechogenic tumours was therefore unexpected 
and is difficult to explain.  Stiffness at SWE is known to be associated with high histological 
grade and large tumour size (17). The weak correlation between high stiffness and high 
upgrade rate is therefore to be expected.    
 
The limitations of this work include being a single centre study where grading has been 
performed by four expert pathologists. However, the size of the study is large with over 100 
events (upgrades from grade 2 to grade 3). Therefore, the borderline nature of some of the 
associations found reflect a true weakness of associations rather than a consequence of small 
sample size. A small percentage of invasive cancers not apparent on US were not included in 
the data as the data source was a US database.  
 
In conclusion, our study has shown that the most significant factor associated with upgrade 
from grade 2 IDC NST at core biopsy to grade 3 on excision was US size.  Other weaker 
associations of upgrade such as micro-calcification on mammography, hyperechogencity on 
US, ER negativity, PR negativity and stiffness at SWE did not maintain significance at 
multivariate analysis. We therefore suggest clinicians need to be aware that lesions over 
15mm in US size which have a core grade of 2 have a 37% chance of being grade 3 on excision 
and this should be considered when deciding pre-operative management. 
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Table 2: 
US size Grade 2 at excision Grade 3 at excision 
<10mm 112 14(11%) 
10-15mm 123 42(25%) 
16-20mm 54 29(35%) 
21-30mm 39 23(37%) 
>30mm 16 11(41%) 
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Table 1 
 Factor Number of patients 
upgraded/total 
Upgrad
e rate 
(%) 
P-value 
Clinical 
factors 
>=55 years old 105/400 26.3 0.497 
< 55 years old 14/63 22.2 
Screening 48/221 21.7 0.060 
Symptomatic 71/242 29.3 
Mammogra
phy 
Spiculation 55/233 23.6 0.300 
No spiculation 64/230 27.8 
Calcification 37/105 35.2 0.011 
No calcification 82/358 22.9 
Ultrasound Circumscribed 22/81 27.2 0.740 
Non-circumscribed 97/382 25.4 
Parallel 87/322 27 0.330 
Non-parallel 32/141 22.7 
Hyperechoic 
feature 
29/78 37.2 0.010 
No hyperechoic 
feature 
90/385 23.4 
Posterior effect 15/43 34.9 0.150 
No posterior effect 104/420 24.8 
Receptor 
Status 
HER2 postive 14/35 40 0.059 
HER 2 negative 106/419 25.4 
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